Research programme: cognitive disorder gene therapy - PTC Therapeutics/University of South Florida

Drug Profile

Research programme: cognitive disorder gene therapy - PTC Therapeutics/University of South Florida

Alternative Names: AGIL-AS - PTC Therapeutics/University of South Florida; Angelman syndrome gene therapy - PTC Therapeutics/University of South Florida; Angelman Syndrome Therapeutics - PTC Therapeutics/USF; AS gene therapy - PTC Therapeutics/University of South Florida; GT-AS; Reelin based therapy - PTC Therapeutics/University of South Florida; Reelin-based gene therapy - PTC Therapeutics/University of South Florida; UBE3a therapy - PTC Therapeutics/University of South Florida

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of South Florida
  • Developer PTC Therapeutics; University of South Florida
  • Class Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Ubiquitin-protein ligase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Angelman syndrome
  • Research Fragile X syndrome

Most Recent Events

  • 23 Aug 2018 Agilis Biotherapeutics has been acquired and merged into PTC Therapeutics
  • 19 Jul 2018 PTC Therapeutics plans a clinical trial for Angelman syndrome in 2020
  • 20 Oct 2017 Pharmacodynamics data from preclinical studies in Angelman syndrome released by Agilis Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top